Novavax begins several rolling regulatory reviews for its COVID-19 vaccine

By The Science Advisory Board staff writers

Novavax has started the rolling review process for authorization of its COVID-19 vaccine, NVX-CoV2373, by multiple regulatory agencies.

The reviews will continue while the company completes its phase III clinical trials in the U.K. and U.S. of its recombinant protein-based vaccine candidate.

To date, Novavax has begun a rolling review with the European Medicines Agency (EMA), U.S. Food and Drug Administration (FDA), U.K. Medicines and Healthcare products Regulatory Agency (MHRA), and Health Canada.

Copyright © 2021

To read this and get access to all of the exclusive content on The Science Advisory Board create a free account or sign-in now.

Member Sign In:
MemberID or email address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?